Covidien

Covidien
Name	Covidien
Type	Public
Fate	Acquired by Medtronic
Successor	Medtronic
Foundation	2007
Defunct	2015
Location	Dublin
Products	Medical devices, surgical instruments, respiratory and monitoring solutions
Industry	Medical devices
Key people	Vincent Forlenza, José E. Almeida, Ronald Bloom
Num employees	42,000 (2014)

Covidien was a multinational medical device company formed in 2007 that manufactured surgical supplies, medical devices, and patient monitoring equipment. Headquartered in Dublin, the company operated globally, supplying hospitals and healthcare providers with consumables, devices, and technologies. Covidien became a major player in the medical device industry before its 2015 acquisition by Medtronic.

History

Covidien was created in 2007 when the Tyco International healthcare business was spun off and rebranded, following strategic moves involving Markel Corporation and corporate restructuring led by executives including Ronald Bloom and Vincent Forlenza. The company expanded through organic growth and acquisitions during the late 2000s and early 2010s, competing with firms such as Johnson & Johnson, Becton Dickinson, Baxter International, and Stryker Corporation. In 2014 Covidien announced a proposed merger with Medtronic, a deal that culminated in a 2015 acquisition and relocation of legal domicile matters connected to Ireland and international tax structuring. The acquisition followed regulatory reviews by authorities including the U.S. Department of Justice and the European Commission.

Products and services

Covidien's portfolio included surgical instruments, stapling devices, hemostats, vascular products, and endomechanical devices used in procedures across specialties like general surgery, neurosurgery, cardiothoracic surgery, and orthopedics. The company produced respiratory and monitoring solutions under brands that competed with offerings from GE Healthcare, Philips Healthcare, and Siemens Healthineers. Consumable products included sutures and wound care items comparable to those from Ethicon and Medline Industries. Covidien also offered minimally invasive technologies and electrosurgical devices relevant to providers such as Mayo Clinic, Cleveland Clinic, and academic centers like Johns Hopkins Hospital.

Operations and corporate structure

Covidien maintained manufacturing facilities and research centers across regions including United States, Ireland, China, and Costa Rica, supplying hospitals in markets such as United Kingdom, Germany, Japan, and Brazil. The corporate governance structure involved a board with members who had ties to firms like BlackRock, The Carlyle Group, and Goldman Sachs. Manufacturing partnerships and supplier relationships connected Covidien to industrial firms such as 3M and logistics providers including UPS and DHL. Sales channels included direct hospital contracts, group purchasing organizations comparable to Premier, Inc. and Vizient, Inc., and distribution agreements with regional distributors in markets like Australia and India.

Mergers and acquisitions

Covidien grew through notable acquisitions and divestitures, integrating businesses from firms including Natus Medical, Kendall Healthcare Products (originally related to Tyco International), and business units that competed with Cardinal Health. The company's most consequential transaction was its 2015 acquisition by Medtronic, a $42.9 billion deal that reshaped the competitive landscape alongside contemporaneous consolidation such as Abbott Laboratories's transactions and mergers within the medical device industry. The acquisition required approvals from antitrust authorities including the U.S. Federal Trade Commission-resembled reviews and coordination with competition bodies in China and Brazil.

Research, innovation, and quality

Covidien invested in research and development adjacent to academic collaborations with institutions like Harvard Medical School, Stanford University, and clinical partnerships involving Mayo Clinic and Cleveland Clinic. Innovations centered on minimally invasive surgery, stapling and sealing technologies, and ventilators and anesthesia delivery systems that intersected with standards from organizations such as American Society of Anesthesiologists and device guidance influenced by Food and Drug Administration pathways. The company published clinical studies and supported investigator-initiated trials at tertiary centers including Massachusetts General Hospital and UCSF Medical Center.

Regulatory and legal matters

As a global device manufacturer, Covidien engaged with regulatory agencies including the Food and Drug Administration, the European Medicines Agency, and national bodies in Australia and Canada for product approvals and post-market surveillance. The company responded to recalls and safety communications that invoked regulatory reporting requirements similar to those handled by peers such as Baxter International and Stryker Corporation. Legal matters involved patent litigation and intellectual property disputes with competitors like Ethicon and Medline Industries, and the acquisition by Medtronic prompted review by competition authorities and shareholder litigation in jurisdictions including Delaware courts.

Corporate social responsibility and philanthropy

Covidien engaged in philanthropic programs and global health partnerships, collaborating with organizations such as Doctors Without Borders, Partners In Health, and health ministries in countries like Haiti and Kenya to support surgical capacity building and disaster relief. Corporate social responsibility initiatives included sustainability efforts aligned with standards from groups like CDP and collaborations with non-governmental entities including World Health Organization-related programs and professional societies such as American College of Surgeons to improve surgical safety and training.

Category:Medical device companies Category:Defunct companies of Ireland Category:Companies acquired by Medtronic